Intellia Therapeutics Stock Alpha and Beta Analysis
| NTLA Stock | USD 10.71 0.80 6.95% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Intellia Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Intellia Therapeutics over a specified time horizon. Remember, high Intellia Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Intellia Therapeutics' market risk premium analysis include:
Beta (0.60) | Alpha (0.32) | Risk 4.81 | Sharpe Ratio (0.11) | Expected Return (0.52) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Intellia |
Intellia Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Intellia Therapeutics market risk premium is the additional return an investor will receive from holding Intellia Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Intellia Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Intellia Therapeutics' performance over market.| α | -0.32 | β | -0.6 |
Intellia Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Intellia Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Intellia Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Intellia Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Intellia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Intellia Therapeutics shares will generate the highest return on investment. By understating and applying Intellia Therapeutics stock market price indicators, traders can identify Intellia Therapeutics position entry and exit signals to maximize returns.
Intellia Therapeutics Return and Market Media
The median price of Intellia Therapeutics for the period between Fri, Nov 29, 2024 and Thu, Feb 27, 2025 is 12.05 with a coefficient of variation of 15.52. The daily time series for the period is distributed with a sample standard deviation of 1.86, arithmetic mean of 11.98, and mean deviation of 1.55. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 7850 shares by Leonard John M of Intellia Therapeutics subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 556 shares by Clark Eliana of Intellia Therapeutics at 12.03 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 7422 shares by Clark Eliana of Intellia Therapeutics at 12.18 subject to Rule 16b-3 | 01/03/2025 |
4 | Insider Trading | 01/13/2025 |
5 | Intellia Therapeutics Announces First Patient Dosed in the HAELO | 01/22/2025 |
6 | Acquisition by Goff Brian of 15409 shares of Intellia Therapeutics subject to Rule 16b-3 | 01/31/2025 |
7 | DEADLINE ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics | 02/12/2025 |
8 | Intellia Therapeutics Among The SmallCap Stocks Insiders Are Selling Recently | 02/14/2025 |
9 | ROSEN, LEADING TRIAL ATTORNEYS, Encourages Intellia Therapeutics, Inc. ... | 02/18/2025 |
10 | Intellia Therapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations | 02/19/2025 |
11 | NTLA Investors are Suing Intellia Therapeutics, Inc. Contact Robbins LLP for More Information | 02/20/2025 |
12 | Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi Korsinsky ... | 02/21/2025 |
13 | NTLA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class ... | 02/25/2025 |
About Intellia Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Intellia or other stocks. Alpha measures the amount that position in Intellia Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 26.39 | 366.82 | 330.14 | 346.65 | PTB Ratio | 2.17 | 2.58 | 2.32 | 2.74 |
Intellia Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Intellia Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Intellia Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Intellia Therapeutics. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Intellia Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Intellia Therapeutics Backtesting, Intellia Therapeutics Valuation, Intellia Therapeutics Correlation, Intellia Therapeutics Hype Analysis, Intellia Therapeutics Volatility, Intellia Therapeutics History and analyze Intellia Therapeutics Performance. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Intellia Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.